Global Flow Cytometry in Oncology Market

Focus on Product Type, Technology, Type of Cancer, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031

Published Year: 2021
SKU: BHP1070SA

5250

Online Access for 1-3 Users. Permission to Print.


In case you require a hard copy, there will be an additional charge of $500. Please email us at [email protected] with your request.

A quick peek into the report

Table of Contents

Download this TOC  

Request a Sample

1 Product Definition

1.1    Inclusion and Exclusion

2 Market Scope

2.1    Scope of the Study
2.2    Key Questions Answered in the Report

3 Research Methodology

3.1    Global Flow Cytometry in Oncology Market: Research Methodology
3.2    Data Sources
         3.2.1    Primary Data Sources
         3.2.2    Secondary Data Sources
3.3    Market Estimation Model
3.4    Criteria for Company Profiling

4 Market Overview

4.1    Market Definition
4.2    Application of Flow Cytometry in Oncology (Hematological vs. Solid Tumors)
4.3    Market Footprint and Growth Potential
4.4    COVID-19 Impact: Global Flow Cytometry in Oncology Market

5 Industry Insights

5.1    Overview
5.2    Legal Requirements and Framework in U.S.
5.3    Legal Requirements and Framework in Europe
5.4    Legal Requirements and Framework in Asia-Pacific
         5.4.1    China
         5.4.2    Japan

6 Market Dynamics

6.1    Overview
6.2    Impact Analysis
6.3    Market Drivers
         6.3.1    Rising Incidence of Hematological Malignancies
         6.3.2    Increasing Fund Infusions for Hematological Malignancies
         6.3.3    Growing Consumer Awareness for Tailored Therapy and Precision Medicine
6.4    Market Restraints
         6.4.1    False Negatives and Positives
         6.4.2    Restricted Specificity Offered by Conventional Flow Cytometry-Based MRD Assessment
6.5    Market Opportunities
         6.5.1    Technological Evolution in the Field of Flow Cytometry
                     6.5.1.1    Emergence of Multiparametric Flow Cytometry for Hematologic Malignancies
                     6.5.1.2    Growing Focus on Next-Generation Flow Cytometry
         6.5.2    Growth in Solid Tumor Applications of Flow Cytometry

7 Competitive Landscape

7.1    Product Launches
7.2    Synergistic Activities
7.3    Acquisitions
7.4    Product Approvals and Business Expansion Activities
7.5    Market Share Analysis, 2019–2020
7.6    Growth Share Analysis
         7.6.1    Growth Share Analysis (by Company)
         7.6.2    Growth Share Analysis (by Technology)
         7.6.3    Growth Share Analysis (by Type of Cancer)
         7.6.4    Growth Share Analysis (by Application)
7.7    Competitive Assessment of Different Technologies Utilized for MRD Testing

8 Global Flow Cytometry in Oncology Market (by Product Type), $Million, 2020-2031

8.1    Overview
8.2    Assays and Kits
8.3    Instruments
8.4    Reagents and Consumables
8.5    Software

9 Global Flow Cytometry in Oncology Market (by Technology), $Million, 2020-2031

9.1    Overview
9.2    Cell-Based
9.3    Bead-Based

10 Global Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031

10.1    Overview
10.2    Hematological Malignancies
           10.2.1    Lymphoma
           10.2.2    Leukemia
           10.2.3    Myeloma
           10.2.4    Other Hematological Malignancies
           10.2.5    Global Flow Cytometry Market for Hematological Malignancies (by Technology)
10.3    Solid Tumors
           10.3.1    Breast Cancer
           10.3.2    Prostate Cancer
           10.3.3    Colorectal Cancer (CRC)
           10.3.4    Lung Cancer
           10.3.5    Other Solid Tumors
           10.3.6    Global Flow Cytometry in Oncology Market for Solid Tumors (by Technology)

11 Global Flow Cytometry in Oncology Market (by Application), $Million, 2020-2031

11.1    Overview
11.2    Translational Research
11.3    Clinical Applications
           11.3.1    Screening and Diagnostics
           11.3.2    Treatment Monitoring

12 Global Flow Cytometry in Oncology Market (by End User), $Million, 2020-2031

12.1    Overview
12.2    Diagnostic Laboratories
12.3    Hospitals and Healthcare Clinics
12.4    Academic and Research Institutions
12.5    Other End Users

13 Global Flow Cytometry in Oncology Market (by Region), $Million, 2020-2031

13.1    Overview
13.2    North America
           13.2.1    U.S.
           13.2.2    Canada
           13.2.3    North America Flow Cytometry in Oncology Market (by Type of Cancer)
13.3    Europe
           13.3.1    Germany
           13.3.2    U.K.
           13.3.3    France
           13.3.4    Italy
           13.3.5    Spain
           13.3.6    Netherlands
           13.3.7    Rest-of-Europe
           13.3.8    Europe Flow Cytometry in Oncology Market (by Type of Cancer)
13.4    Asia-Pacific (APAC)
           13.4.1    China
           13.4.2    Japan
           13.4.3    India
           13.4.4    Australia
           13.4.5    South Korea
           13.4.6    Singapore
           13.4.7    Rest-of-Asia-Pacific (RoAPAC)
           13.4.8    Asia-Pacific Flow Cytometry in Oncology Market (by Type of Cancer)
13.5    Latin America (LATAM0
           13.5.1    Brazil
           13.5.2    Mexico
           13.5.3    Rest-of-Latin America (RoLA)
           13.5.4    Latin America Flow Cytometry in Oncology Market (by Type of Cancer)
13.6    Rest-of-the-World (RoW)
           13.6.1    Rest-of-the-World Flow Cytometry in Oncology Market (by Type of Cancer)

14 Company Profiles

14.1    Overview
14.2    Agilent Technologies, Inc.
           14.2.1    Company Overview
           14.2.2    Role of Agilent Technologies, Inc. in the Global Flow Cytometry in Oncology Market
           14.2.3    Financials
           14.2.4    Key Insights About Financial Health of the Company
           14.2.5    SWOT Analysis
14.3    Apogee Flow Systems Ltd.
           14.3.1    Company Overview
           14.3.2    Role of Apogee Flow Systems Ltd. in the Global Flow Cytometry in Oncology Market
           14.3.3    SWOT Analysis
14.4    Becton, Dickinson and Company
           14.4.1    Company Overview
           14.4.2    Role of Becton, Dickinson and Company in the Global Flow Cytometry in Oncology Market
           14.4.3    Financials
           14.4.4    Key Insights About Financial Health of the Company
           14.4.5    SWOT Analysis
14.5    bioAffinity Technologies, Inc.
           14.5.1    Company Overview
           14.5.2    Role of bioAffinity Technologies, Inc. in the Global Flow Cytometry in Oncology Market
           14.5.3    SWOT Analysis
14.6    Bio-Rad Laboratories, Inc.
           14.6.1    Company Overview
           14.6.2    Role of Bio-Rad Laboratories, Inc. in the Global Flow Cytometry in Oncology Market
           14.6.3    Financials
           14.6.4    Key Insights About Financial Health of the Company
           14.6.5    SWOT Analysis
14.7    Bio-Techne Corporation
           14.7.1    Company Overview
           14.7.2    Role of Bio-Techne Corporation in the Global Flow Cytometry in Oncology Market
           14.7.3    Financials
           14.7.4    Key Insights About Financial Health of the Company
           14.7.5    SWOT Analysis
14.8    Cytek Biosciences
           14.8.1    Company Overview
           14.8.2    Role of Cytek Biosciences in the Global Flow Cytometry in Oncology Market
           14.8.3    SWOT Analysis
14.9    Cytognos, S.L.
           14.9.1    Company Overview
           14.9.2    Role of Cytognos, S.L. in the Global Flow Cytometry in Oncology Market
           14.9.3    SWOT Analysis
14.10    Danaher Corporation
             14.10.1    Company Overview
             14.10.2    Role of Danaher Corporation in the Global Flow Cytometry in Oncology Market
             14.10.3    Financials
             14.10.4    Key Insights About Financial Health of the Company
             14.10.5    SWOT Analysis
14.11    Miltenyi Biotec B.V. & Co. KG
             14.11.1    Company Overview
             14.11.2    Role of Miltenyi Biotec B.V. & Co. KG in the Global Flow Cytometry in Oncology Market
             14.11.3    SWOT Analysis
14.12    Laboratory Corporation of America Holdings
             14.12.1    Company Overview
             14.12.2    Role of Laboratory Corporation of America Holdings in the Global Flow Cytometry in Oncology Market
             14.12.3    Financials
             14.12.4    SWOT Analysis
14.13    Luminex Corporation
             14.13.1    Company Overview
             14.13.2    Role of Luminex Corporation in the Global Flow Cytometry in Oncology Market
             14.13.3    Financials
             14.13.4    Key Insights About Financial Health of the Company
             14.13.5    SWOT Analysis
14.14    NeoGenomics Laboratories, Inc.
             14.14.1    Company Overview
             14.14.2    Role of NeoGenomics Laboratories, Inc. in the Global Flow Cytometry in Oncology Market
             14.14.3    Financials
             14.14.4    Key Insights about Financial Health of the Company
             14.14.5    SWOT Analysis
14.15    Sony Corporation
             14.15.1    Company Overview
             14.15.2    Role of Sony Corporation in the Global Flow Cytometry in Oncology Market
             14.15.3    Financials
             14.15.4    Key Insights About Financial Health of the Company
             14.15.5    SWOT Analysis
14.16    Thermo Fisher Scientific Inc.
             14.16.1    Company Overview
             14.16.2    Role of Thermo Fisher Scientific Inc. in the Global Flow Cytometry in Oncology Market
             14.16.3    Financials
             14.16.4    Key Insights About Financial Health of the Company
             14.16.5    SWOT Analysis

List of Tables

Table 6.1:    Likert Scale
Table 6.2:    Impact Analysis of Market Drivers
Table 6.3:    Impact Analysis of Market Restraints

List of Figures

Figure 1:    Prevalence of Hematological Malignancies in the U.S., 2013-2016
Figure 2:    National Cancer Institute (NCI) of the U.S., Fiscal Budget Year-on-Year,  2013-2018
Figure 3:    Impact Analysis of Market Drivers and Market Challenges on Global Flow Cytometry in Oncology Market
Figure 4:    Global Flow Cytometry in Oncology Market (by Product Type), $Million, 2020 and 2031
Figure 5:    Global Flow Cytometry in Oncology Market (by Technology), $Million, 2020 and 2031
Figure 6:    Global Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020 and 2031
Figure 7:    Global Flow Cytometry in Oncology Market (by Application), $Million,  2020 and 2031
Figure 8:    Global Flow Cytometry in Oncology Market (by End User), $Million,  2020 and 2031
Figure 9:    Global Flow Cytometry in Oncology: Market Snapshot
Figure 2.1:    Market Segmentation of Global Flow Cytometry in Oncology Market
Figure 3.1:    Global Flow Cytometry in Oncology Market: Methodology
Figure 3.2:    Primary Research Methodology
Figure 3.3:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4:    Top-Down Approach (Segment-Wise Analysis)
Figure 4.1:    Global Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 4.2:    Global Flow Cytometry in Oncology Market: COVID-19 Impact
Figure 6.1:    Global Incidence and Mortality Rate for Individual Hematological Conditions, 2016
Figure 6.2:    Estimated New Cases of Hematological Cancer, 2020
Figure 7.1:    Share of Key Developments and Strategies, January 2017–May 2021
Figure 7.2:    Number of Product Launches (by Company), January 2017–May 2021
Figure 7.3:    Share of Synergistic Activities (by Company), January 2017-May 2021
Figure 7.4:    Share of Acquisitions (by Company), January 2017–May 2021
Figure 7.5:    Market Share Analysis for Global Flow Cytometry in Oncology Market, $Million, 2019 and 2020
Figure 7.6:    Growth Share Analysis for Global Flow Cytometry in Oncology Market  (by Company), 2020
Figure 7.7:    Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Technology), 2020-2031
Figure 7.8:    Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Type of Cancer), 2020-2031
Figure 7.9:    Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Application), 2020-2031
Figure 7.10:    Comparative Assessment of Technologies Used in MRD Testing
Figure 8.1:    Global Flow Cytometry in Oncology Market (by Product Type)
Figure 8.2:    Global Flow Cytometry in Oncology Market (by Product Type), $Million, 2020 and 2031
Figure 8.3:    Global Flow Cytometry in Oncology Market (Assays and Kits), $Million,  2020-2031
Figure 8.4:    Global Flow Cytometry in Oncology Market (Instruments), $Million,  2020-2031
Figure 8.5:    Global Flow Cytometry in Oncology Market (Reagents and Consumables), $Million, 2020-2031
Figure 8.6:    Global Flow Cytometry in Oncology Market (Software), $Million, 2020-2031
Figure 9.1:    Global Flow Cytometry in Oncology Market (by Technology)
Figure 9.2:    Global Flow Cytometry in Oncology Market (by Technology), $Million, 2020 and 2031
Figure 9.3:    Global Flow Cytometry in Oncology Market (Cell-Based), $Million,  2020-2031
Figure 9.4:    Global Flow Cytometry in Oncology Market (Bead-Based), $Million,  2020-2031
Figure 10.1:    Global Flow Cytometry in Oncology Market (by Type of Cancer)
Figure 10.2:    Global Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020 and 2031
Figure 10.3:    Global Flow Cytometry in Oncology Market (by Hematological Malignancies), $Million, 2020-2031
Figure 10.4:    Global Flow Cytometry in Oncology Market (by Hematological Malignancies), $Million, 2020 and 2031
Figure 10.5:    Global Flow Cytometry in Oncology Market (Lymphoma), $Million,  2020-2031
Figure 10.6:    Global Flow Cytometry in Oncology Market (Leukemia), $Million,  2020-2031
Figure 10.7:    Global Flow Cytometry in Oncology Market (Myeloma), $Million,  2020-2031
Figure 10.8:    Global Flow Cytometry in Oncology Market (Other Hematological Malignancies), $Million, 2020-2031
Figure 10.9:    Global Flow Cytometry in Oncology Market for Hematological Malignancies (by Technology), $Million, 2020-2031
Figure 10.10:    Global Flow Cytometry in Oncology Market (by Solid Tumors), $Million, 2020-2031
Figure 10.11:    Global Flow Cytometry in Oncology Market (by Solid Tumors), $Million, 2020 and 2031
Figure 10.12:    Global Flow Cytometry in Oncology Market (Breast Cancer), $Million, 2020-2031
Figure 10.13:    Global Flow Cytometry in Oncology Market (Prostate Cancer), $Million, 2020-2031
Figure 10.14:    Global Flow Cytometry in Oncology Market (Colorectal Cancer), $Million, 2020-2031
Figure 10.15:    Global Flow Cytometry in Oncology Market (Lung Cancer), $Million, 2020-2031
Figure 10.16:    Global Flow Cytometry in Oncology Market (Other Solid Tumors), $Million, 2020-2031
Figure 10.17:    Global Flow Cytometry in Oncology Market for Solid Tumors (by Technology), $Million, 2020-2031
Figure 11.1:    Global Flow Cytometry in Oncology Market (by Application)
Figure 11.2:    Global Flow Cytometry in Oncology Market (by Application), $Million,  2020-2031
Figure 11.3:    Global Flow Cytometry in Oncology Market (Translational Research), $Million, 2020-2031
Figure 11.4:    Global Flow Cytometry in Oncology Market (by Clinical Applications), $Million, 2020 and 2031
Figure 11.5:    Global Flow Cytometry in Oncology Market (Screening and Diagnostics), $Million, 2020-2031
Figure 11.6:    Global Flow Cytometry in Oncology Market (Treatment Monitoring), $Million, 2020-2031
Figure 12.1:    Global Flow Cytometry in Oncology Market (by End User)
Figure 12.2:    Global Flow Cytometry in Oncology Market (by End User), $Million,  2020-2031
Figure 12.3:    Global Flow Cytometry in Oncology Market (Diagnostic Laboratories), $Million, 2020-2031
Figure 12.4:    Global Flow Cytometry in Oncology Market (Hospitals and Healthcare Clinics), $Million, 2020-2031
Figure 12.5:    Global Flow Cytometry in Oncology Market (Academic and Research Institutions), $Million, 2020-2031
Figure 12.6:    Global Flow Cytometry in Oncology Market (Other End Users), $Million, 2020-2031
Figure 13.1:    Global Flow Cytometry in Oncology Market (by Region)
Figure 13.2:    Global Flow Cytometry in Oncology Market (by Region), $Million,  2020-2031
Figure 13.3:    Global Flow Cytometry in Oncology Market (by Region), $Million,  2020-2031
Figure 13.4:    North America Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.5:    North America: Market Dynamics
Figure 13.6:    North America Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
Figure 13.7:    U.S. Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.8:    Canada Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.9:    North America Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
Figure 13.10:    Europe Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.11:    Europe: Market Dynamics
Figure 13.12:    Europe Flow Cytometry in Oncology Market (by Country), $Million,  2020-2031
Figure 13.13:    Germany Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.14:    U.K. Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.15:    France Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.16:    Italy Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.17:    Spain Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.18:    Netherlands Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.19:    Rest-of-Europe Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.20:    Europe Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
Figure 13.21:    Asia-Pacific Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.22:    Asia-Pacific: Market Dynamics
Figure 13.23:    APAC Flow Cytometry in Oncology Market (by Country), $Million,  2020-2031
Figure 13.24:    China Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.25:    Japan Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.26:    India Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.27:    Australia Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.28:    South Korea Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.29:    Singapore Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.30:    RoAPAC Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.31:    APAC Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
Figure 13.32:    Latin America Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.33:    Latin America: Market Dynamics
Figure 13.34:    Latin America Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
Figure 13.35:    Brazil Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.36:    Mexico Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.37:    RoLA Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.38:    LATAM Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
Figure 13.39:    Rest-of-the-World Flow Cytometry in Oncology Market, $Million,  2020-2031
Figure 13.40:    Rest-of-the-World Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
Figure 14.1:    Total Number of Companies Profiles
Figure 14.2:    Agilent Technologies, Inc.: Product Portfolio
Figure 14.3:    Agilent Technologies, Inc.: Overall Financials, 2018-2020
Figure 14.4:    Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020
Figure 14.5:    Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
Figure 14.6:    Agilent Technologies, Inc.: R&D Expenditure, 2018-2020
Figure 14.7:    Agilent Technologies, Inc.: SWOT Analysis
Figure 14.8:    Apogee Flow Systems Ltd.: Product Portfolio
Figure 14.9:    Apogee Flow Systems Ltd.: SWOT Analysis
Figure 14.10:    Becton, Dickinson and Company: Product Portfolio
Figure 14.11:    Becton, Dickinson and Company: Overall Financials, 2018-2020
Figure 14.12:    Becton, Dickinson and Company: Revenue (by Segment), 2018-2020
Figure 14.13:    Becton, Dickinson and Company: Revenue (by Region), 2018-2020
Figure 14.14:    Becton, Dickinson and Company: R&D Expenditure, 2018-2020
Figure 14.15:    Becton, Dickinson and Company: SWOT Analysis
Figure 14.16:    bioAffinity Technologies, Inc.: Product Portfolio
Figure 14.17:    bioAffinity Technologies, Inc.: SWOT Analysis
Figure 14.18:    Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 14.19:    Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020
Figure 14.20:    Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2018-2020
Figure 14.21:    Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020
Figure 14.22:    Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020
Figure 14.23:    Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 14.24:    Bio-Techne Corporation: Product Portfolio
Figure 14.25:    Bio-Techne Corporation: Overall Financials, 2018-2020
Figure 14.26:    Bio-Techne Corporation: Revenue (by Segment), 2018-2020
Figure 14.27:    Bio-Techne Corporation: Revenue (by Region), 2018-2020
Figure 14.28:    Bio-Techne Corporation: R&D Expenditure, 2018-2020
Figure 14.29:    Bio-Techne Corporation: SWOT Analysis
Figure 14.30:    Cytek Biosciences: Product Portfolio
Figure 14.31:    Cytek Biosciences: SWOT Analysis
Figure 14.32:    Cytognos, S.L.: Product Portfolio
Figure 14.33:    Cytognos, S.L.: SWOT Analysis
Figure 14.34:    Danaher Corporation: Product Portfolio
Figure 14.35:    Danaher Corporation: Overall Financials, 2018-2020
Figure 14.36:    Danaher Corporation: Revenue (by Segment), 2018-2020
Figure 14.37:    Danaher Corporation: Revenue (by Region), 2018-2020
Figure 14.38:    Danaher Corporation: R&D Expenditure, 2018-2020
Figure 14.39:    Danaher Corporation: SWOT Analysis
Figure 14.40:    Miltenyi Biotec B.V. & Co. KG: Product Portfolio
Figure 14.41:    Miltenyi Biotec B.V. & Co. KG: SWOT Analysis
Figure 14.42:    Laboratory Corporation of America Holdings: Service Portfolio
Figure 14.43:    Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
Figure 14.44:    Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
Figure 14.45:    Laboratory Corporation of America Holdings: SWOT Analysis
Figure 14.46:    Luminex Corporation: Product Portfolio
Figure 14.47:    Luminex Corporation: Overall Financials, 2018-2020
Figure 14.48:    Luminex Corporation: Revenue (by Segment), 2018-2020
Figure 14.49:    Luminex Corporation: Revenue (by Region), 2018-2020
Figure 14.50:    Luminex Corporation: R&D Expenditure, 2018-2020
Figure 14.51:    Luminex Corporation: SWOT Analysis
Figure 14.52:    NeoGenomics Laboratories, Inc.: Service Portfolio
Figure 14.53:    NeoGenomics Laboratories, Inc.: Overall Financials, 2018-2020
Figure 14.54:    NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2018-2020
Figure 14.55:    NeoGenomics Laboratories, Inc.: R&D Expenditure, 2018-2020
Figure 14.56:    NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 14.57:    Sony Corporation: Product Portfolio
Figure 14.58:    Sony Corporation: Overall Financials, 2018-2020
Figure 14.59:    Sony Corporation: Revenue (by Segment): 2018-2020
Figure 14.60:    Sony Corporation: Revenue (by Region), 2018-2020 (E)
Figure 14.61:    Sony Corporation: R&D Expenditure, 2018-2020 (E)
Figure 14.62:    Sony Corporation: SWOT Analysis
Figure 14.63:    Thermo Fisher Scientific, Inc.: Product Portfolio
Figure 14.64:    Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
Figure 14.65:    Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
Figure 14.66:    Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
Figure 14.67:    Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 14.68:    Thermo Fisher Scientific Inc.: SWOT Analysis

You may also like

Published Year: 2020

Global MRD Testing Market: Focus on Technology, Application, End User, Region and Competitive Landsc

The global market for MRD testing is predicted to grow at a CAGR of 15.64% over the forecast...

 
Published Year: 2019

Global Hematologic Malignancies Testing Market: Focus on Product, Disease, Technology, End User, Reg

The hematologic malignancies testing industry analysis by BIS Research projects the market to...

 

Global Flow Cytometry in Oncology Market

Focus on Product Type, Technology, Type of Cancer, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031